Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14345376 | 0.88 | ATM (0.39) | MEN1PKMKMT2AATMGRM5 | |
| SCHEMBL19643692 | 0.88 | MEN1 (0.39) | TLR7MEN1PKMKMT2AATM | |
| SCHEMBL19643695 | 0.88 | MEN1 (0.39) | TLR7MEN1PKMKMT2AATM | |
| SCHEMBL4307994 | 0.86 | NUDT1 (0.44) | MEN1PKMKMT2AATMGRM5 | |
| SCHEMBL15923383 | 0.83 | ABCG2 (0.35) | MEN1PKMKMT2AGRM5CYP1A2 | |
| SCHEMBL3861877 | 0.82 | TNF (0.42) | MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL3860553 | 0.82 | EGLN2 (0.40) | TLR7GRM5 | |
| SCHEMBL24604515 | 0.82 | LRRK2 (0.38) | TLR7MEN1PKMKMT2AATM | |
| SCHEMBL3865789 | 0.81 | EGFR (0.35) | MEN1KMT2ACYP1A2MAPTNPSR1 | |
| SCHEMBL3862247 | 0.81 | MAPK1 (0.42) | MAPTNPSR1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683669-A2 | COMBINATIONS AND METHODS FOR ENHANCING CHECKPOINT INHIBITOR THERAPIES IN CANCER TREATMENT | Purdue Research Foundation (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250352652-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC DISEASE STATES AND CANCER | PURDUE RESEARCH FOUNDATION | 2025-11-20 | — | — | US | disclosed |
| US-20250269036-A1 | METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT | PURDUE RESEARCH FOUNDATION | 2025-08-28 | — | — | US | disclosed |
| US-12397059-B2 | Compounds and methods for the treatment and prevention of fibrotic disease states and cancer | PURDUE RESEARCH FOUNDATION (US) | 2025-08-26 | — | — | US | disclosed |
| WO-2025103490-A1 | N-OXIDE IMMUNE AGONISTS ACTIVATION BY RADIOTHERAPY | Beijing Changping Laboratory (CN) | 2025-05-22 | — | — | WO | disclosed |
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2025-01-30 | — | — | US | disclosed |
| US-12139483-B2 | Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | PHARMA CINQ, LLC (US) | 2024-11-12 | — | — | US | disclosed |
| WO-2024197318-A2 | COMBINATIONS AND METHODS FOR ENHANCING CHECKPOINT INHIBITOR THERAPIES IN CANCER TREATMENT | PURDUE RESEARCH FOUNDATION (US) | 2024-09-26 | — | — | WO | disclosed |
| CN-117858706-A | Methods of enhancing engineered cell therapies in cancer treatment | 普渡研究基金会 | 2024-04-09 | — | — | CN | disclosed |
| US-20230355750-A1 | KINETICALLY ACTING ADJUVANT ENSEMBLE | Progeneer Inc. (KR) | 2023-11-09 | — | — | US | disclosed |
| EP-0389302-B1 | Olefinic 1H-imidazo [4,5-c]quinolin-4-amines | RIKER LABORATORIES INC (US) | 1994-08-31 | — | — | EP | disclosed |
| EP-0582581-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO 4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-02-16 | — | — | EP | disclosed |
| US-5266575-A | Immunomodulator, viricides | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-11-30 | — | — | US | disclosed |
| WO-1993009119-A1 | ANTIVIRAL 2-ETHYL-1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-05-13 | — | — | WO | disclosed |
| WO-1992015582-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-17 | — | — | WO | disclosed |
| US-5037986-A | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0389302-A1 | Olefinic 1H-imidazo [4,5-c]quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1990-09-26 | — | — | EP | disclosed |
| US-4929624-A | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-05-29 | — | — | US | disclosed |
| US-4698348-A | 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents | RIKER LABORATORIES, INC. (US) | 1987-10-06 | — | — | US | disclosed |
| US-4689338-A | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use | RIKER LABORATORIES, INC. (US) | 1987-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12397059-B2 | Compounds and methods for the treatment and prevention of fibrotic disease states and cancer | MSR1, MIF, MMP12 | TLR7 684/4885MEN1 1888/4885PKM 1085/4885 |
| US-20230355750-A1 | KINETICALLY ACTING ADJUVANT ENSEMBLE | GPX1, GSS, IFNG | TLR7 377/4885MEN1 4003/4885PKM 263/4885 |
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AADAC, CASP1, AAAS | TLR7 380/4885MEN1 395/4885PKM 1453/4885 |
| US-20250269036-A1 | METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT | CD47, FOLR1, CD14 | TLR7 355/4885MEN1 798/4885PKM 424/4885 |
| US-12139483-B2 | Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | NOD1, NLRP3, AADAC | TLR7 456/4885MEN1 1439/4885PKM 1234/4885 |
| US-20250352652-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC DISEASE STATES AND CANCER | MSR1, MIF, MMP12 | TLR7 684/4885MEN1 1888/4885PKM 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.